T cell engineering has changed the landscape of cancer immunotherapy. Chimeric antigen
receptor T cells have demonstrated a remarkable efficacy in the treatment of B cell …

To redirect T cells against tumor cells, T cells can be engineered ex vivo to express cancer-
antigen specific T cell receptors (TCRs), generating products known as TCR-engineered T …

Survivin is the smallest member of the inhibitor of apoptosis protein family, which has key
roles in regulating cell division and inhibiting apoptosis by blocking caspase activation …

Options for targeted therapy of T-cell malignancies remain scarce. Recent clinical trials
demonstrated that chimeric antigen receptors (CARs) can effectively redirect T lymphocytes …

Recent advances in neoantigen research have accelerated the development of tumor
immunotherapies, including adoptive cell therapies (ACTs), cancer vaccines and antibody …

T cells are critical in destroying cancer cells by recognizing antigens presented by MHC
molecules on cancer cells or antigen-presenting cells. Identifying and targeting cancer …

Survivin is one of the rare proteins that is differentially expressed in normal and cancer cells
and is directly or indirectly involved in numerous pathways required for tumor maintenance …

Purpose: The development of safe and effective chimeric antigen receptor (CAR) T-cell
therapy for acute myeloid leukemia (AML) has largely been limited by the concomitant …

Monoclonal antibodies are among the most clinically effective drugs used to treat cancer.
However, their target repertoire is limited as there are relatively few tumor-specific or tumor …

T cell receptor (TCR)-based adoptive T cell therapies (ACT) hold great promise for the
treatment of cancer, as TCRs can cover a broad range of target antigens. Here we …